Review decision – July 2020
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA433; Apremilast for treating active psoriatic arthritis and TA445; Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to DMARDs.
We did not identify any new clinical evidence that would change the existing recommendations in TA433 and TA445. There are no changes to the marketing authorisations or the prices. There is no new evidence on comparative effectiveness for certolizumab pegol, secukinumab, or apremilast compared with biologics or each other for treating psoriatic arthritis.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently, TA433 and TA445 will move to the ‘static list’ of technology appraisals.
This page was last updated: